Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal

Reuters

05/09

Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal

Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2534197206"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534197206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534197206?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 06:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534197206","market":"nz","top_or_hot":-1,"title":"Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-09 06:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL5Tj3Ph:1","article_id":"2534197206","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534197206","pubTimestamp":1746743984,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal. Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib , in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01167":"加科思-B","BK1574":"生物医药B类股"},"translate_title":"Jacobio Pharmaceuticals宣布在著名期刊发表SHP2抑制剂Sitneprotafib联合治疗数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":0.9},"content_text":"Jacobio Pharmaceuticals Announces Publication of SHP2 Inhibitor Sitneprotafib Combination Therapy Data in Prestigious Journal\n    \n\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced a significant advancement in their clinical research with the publication of data on their SHP2 inhibitor, sitneprotafib (JAB-3312), in the prestigious journal, Clinical Cancer Research. The study showcases the potential of sitneprotafib in enhancing anti-tumor activity, particularly when combined with the KRAS G12C inhibitor glecirasib. The research highlights preclinical and clinical case studies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies. This development aligns with Jacobio's commitment to pioneering innovative treatments in oncology, reinforcing their vision to become a global leader in drug research and development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on May 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}